StockData

Biogen vs Vertex Pharmaceuticals

BIIB and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIIB and VRTX compare

Vertex Pharmaceuticals is the larger company, worth 3.6 times as much as Biogen ($137B against $37.5B).

On earnings, Vertex Pharmaceuticals is cheaper: it trades at 31.4× trailing earnings, against 108× for Biogen.

Vertex Pharmaceuticals grew revenue faster over the last twelve months (10.2% versus 2.3% for Biogen).

Vertex Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.0% compared with 3.4% at Biogen.

Vertex Pharmaceuticals scores higher on the StockData Score (15 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIIBVRTX
Size and price
Market cap$37.5B$137B
Share price$253.40$538.60
Change, 1 year56.9%24.0%
Change, 5 years−1.5%195%
Beta (5Y)0.510.52
Employees7,500600K
StockData Score
Total score415 (better)
Valuation score1 (better)0
Growth score03 (better)
Performance score16 (better)
Health score26 (better)
Dividend score00
Valuation
P/E108×31.4× (better)
P/S3.6× (better)10.8×
P/B–6.7×
EV/EBITDA22.2× (better)25.7×
P/FCF18.1× (better)36.0×
PEG–5.12
FCF yield5.5% (better)2.8%
Fair value$163.40$426.36
Margin of safety−55.1%−26.3% (better)
Growth
Revenue growth (TTM)2.3%10.2% (better)
Revenue growth, 5Y average−6.0%14.1% (better)
Net income growth (TTM)−78.4%21.1% (better)
EPS growth (TTM)−78.7%22.4% (better)
EPS growth, 5Y average−18.7%8.3% (better)
Profitability
Gross margin74.0%86.0% (better)
Operating margin–38.0%
Net margin3.4%35.0% (better)
FCF margin20.1%30.2% (better)
Return on equity–23.5%
Return on invested capital–34.4%
Financial health
Debt / equity–0.00
Current ratio1.953.19 (better)
Altman Z-score3.0913.63 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Buyback yield–1.5%
Shareholder yield0.00%1.5% (better)
Ownership
Held by institutions96.2%95.6%
Held by insiders0.21%0.22%
Insider net buying, 12 months−$905K (better)−$131M
Superinvestors holding11
Short interest, % of float3.7%1.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.